Canada · Delayed Price · Currency is CAD Devonian Health Group Company Description
Devonian Health Group Inc. engages in the development of botanical drugs.
Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis.
The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; Dexlansoprazole; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name.
Devonian Health Group Inc. is headquartered in Québec, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Andre Boulet |
Contact Details
Address: 360, rue des Entrepreneurs Québec, Quebec G5V 4T1 Canada | |
| Phone | 514 248 7509 |
| Website | groupedevonian.com |
Stock Details
| Ticker Symbol | GSD |
| Exchange | TSX Venture Exchange |
| Fiscal Year | August - July |
| Reporting Currency | CAD |
| ISIN Number | CA2518341078 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andre P. Boulet Ph.D. | Chief Operating Officer, Chief Executive Officer, Chief Scientific Officer and Chair of the Board |
| Luc D. Gregoire CA, CPA | Executive Vice President of Strategy and Director |
| Viktoria Krasteva | Chief Financial Officer |